Abbott Diabetes Care has recalled some of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors for people ...

The Food and Drug Administration (FDA) has now identified the recall of certain FreeStyle Libre glucose monitor sensors as ...

This is now a Class I recall, meaning that the use of these continuous glucose monitoring systems could cause serious health ...

Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre ...

Abbott (NYSE:ABT) is facing an FDA warning letter alleging quality system regulation violations related to FreeStyle Libre ...

Abbott has been hit with a slew of complaints from the FDA in a warning letter related to its continuous glucose monitor (CGM ...

Abbott Laboratories (ABT) stock is down as the FDA classifies the company's recent recall of FreeStyle Libre 3 glucose ...

Feb 4 (Reuters) - The U.S. Food and Drug Administration on Wednesday classified Abbott's recall of certain glucose monitoring ...

Feb 4 (Reuters) - Medical device maker Abbott Laboratories has reported 860 serious injuries linked to the recall of some of ...

FreeStyle Libre 3 and 3 Plus are continuous glucose monitoring devices indicated for the management of diabetes in patients aged 4 years and older.

The Food and Drug Administration has identified a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors by Abbott Diabetes Care due to incorrect glucose readings that are ...

Boone Health said Abbott has been assisting with the redistribution of new monitors Freestyle Libre 3 and 3 Plus since recall.